Glycine

Catalog No.S4821 Synonyms: 2-Aminoacetic acid, Aminoacetic acid, Glycocoll

For research use only.

Glycine (2-Aminoacetic acid, Aminoacetic acid, Glycocoll) is a non-essential, non-polar, non-optical, glucogenic amino acid that is primarily found in gelatin and silk fibroin. It is involved in the body's production of DNA, phospholipids and collagen, and in release of energy.

Glycine Chemical Structure

CAS No. 56-40-6

Selleck's Glycine has been cited by 2 Publications

Purity & Quality Control

Related Other Products

Biological Activity

Description Glycine (2-Aminoacetic acid, Aminoacetic acid, Glycocoll) is a non-essential, non-polar, non-optical, glucogenic amino acid that is primarily found in gelatin and silk fibroin. It is involved in the body's production of DNA, phospholipids and collagen, and in release of energy.
Targets
MT2 receptor [1] MT1 receptor [1]
9.8(pKi) 9.45(pKi)
In vitro

Glycine significantly increases the MG-63 cell proliferation in a dosedependent manner. Activity of alkaline phosphatase (ALP) and phosphorylation of extracellular-signal-regulated kinase are increased by glycine in MG-63 cells. Glycine also increases the BrdU-incorporation and Ki-67 mRNA expression in MCF-7 cells, induces the up-regulation of estrogen receptor-β mRNA expression and estrogen response element-luciferase activity in MG-63 and MCF-7 cells[2].

In vivo Glycine is the most abundant amino acid in the body and is involved in multiple metabolic pathways. Circulating glycine levels in humans, rats and mice, cats, and dogs range from 0.2-0.4 mM. In rabbits and pigs, they are 1-1.5 mM. Intracellular concentrations are much higher, particularly in renal proximal tubules, which reabsorb filtered glycine and reach 4–10x circulating levels depending on whether they are being actively perfused. Glycine has been reported to lower blood pressure in an NMDA-sensitive fashion[1]. Glycine has an estrogen-like osteoprotective effect in menopause models. It significantly increases the ALP activity, enhances bone mineral density, trabecular number, and connectivity density in OVX mice[2].

Protocol (from reference)

Cell Research:

[2]

  • Cell lines: MG-63 osteoblast cell line, MCF-7 estrogen-dependent cell line
  • Concentrations: 0.1, 1, and 10 μg/ml
  • Incubation Time: 48 h
  • Method:

    --

Animal Research:

[2]

  • Animal Models: Seven-week-old female Balb/c mice
  • Dosages: 10 mg/kg
  • Administration: orally

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 75.07
Formula

C2H5NO2

CAS No. 56-40-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C(C(=O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05478525 Not yet recruiting Drug: GLY-200|Drug: Placebo Type 2 Diabetes Glyscend Inc. August 1 2022 Phase 2
NCT05270525 Not yet recruiting Drug: Ensifentrine|Drug: Placebo COPD Verona Pharma plc|University of Alabama at Birmingham April 1 2022 Phase 2
NCT05319262 Completed Radiation: Pink noise exposure|Radiation: Traffic noise Noise Exposure|Sleep Disturbance|Sleep Hygiene|Metabolic Disturbance|Cognitive Change Göteborg University|University of Pennsylvania|University of Manitoba April 24 2022 Not Applicable
NCT05098470 Recruiting Drug: Metformin|Drug: Insulin Glargine|Drug: Dorzagliatin Type 2 Diabetes University of Virginia March 7 2022 Phase 3
NCT05120986 Withdrawn Other: IND/GLY/MF Asthma Novartis Pharmaceuticals|Novartis February 15 2022 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Glycine | Glycine supplier | purchase Glycine | Glycine cost | Glycine manufacturer | order Glycine | Glycine distributor